LANXESS

LANXESS IS NO GERMAN ARKEMA QUITE YET (REDUCE; +8% UPSIDE)

01/10/24 -" Lanxess’ (Reduce; Germany) equity story is a difficult one. At first sight, the company seems to have the portfolio rotation gene, but there is hardly any positive effect to be identified.  Lanxess ..."

PDF page sample
Pages
60
Language
English
Published on
01/10/24
Download
You may also be interested by these reports :
12/09/25
There was a change of analyst for the coverage of Slitronic AG. We have now revised our figures for the company and incorporated the latest Q2 ...
02/09/25
We last commented on Yara (ADD ; Norway) around 13 months ago, taking a positive stance on the global fertilizer manufacturer, largely backed by the ...
29/08/25
For 2025, the upgrade to EPS stems from the factors below: 1. The largest contributor to the increase – update to the impact of FX on financial ...
28/08/25
Subdued 9M results – Slight guidance trim, funding visibility remains key

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO